Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 542

1.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group.

J Infect Dis. 2006 Dec 15;194(12):1661-71. Epub 2006 Nov 3.

PMID:
17109337
[PubMed - indexed for MEDLINE]
Free Article
2.
3.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

PMID:
19843557
[PubMed - indexed for MEDLINE]
Free Article
4.

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.

Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W, Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, Ippolito T, Hanson C, Gregory T, Heyward WL, Berman P, Francis D.

AIDS Res Hum Retroviruses. 2000 May 1;16(7):655-63.

PMID:
10791876
[PubMed - indexed for MEDLINE]
5.

Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003.

Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, Pitisuttithum P, Tappero JW, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; Bangkok Vaccine Evaluation Group.

Addiction. 2009 Feb;104(2):235-42. doi: 10.1111/j.1360-0443.2008.02436.x.

PMID:
19149819
[PubMed - indexed for MEDLINE]
6.

Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.

Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, Heyward WL, Francis DP.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1160-5. Erratum in: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1669.

PMID:
15319676
[PubMed - indexed for MEDLINE]
7.

Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand.

Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, Sujarita S, Srisuwanvilai LO, Young NL, Wasi C, Subbarao S, Heyward WL, Esparza L, Choopanya K.

AIDS. 2001 Feb 16;15(3):397-405.

PMID:
11273220
[PubMed - indexed for MEDLINE]
8.

A comparison of full-length glycoprotein 120 from incident HIV type 1 subtype E and B infections in Bangkok injecting drug users with prototype E and B strains that are components of a candidate vaccine.

Phan KO, Callahan ME, Vanichseni S, Hu DJ, Raktham S, Young N, Choopanya K, Mastro TD, Subbarao S.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1445-50.

PMID:
11018864
[PubMed - indexed for MEDLINE]
9.

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group.

J Infect Dis. 2005 Mar 1;191(5):654-65. Epub 2005 Jan 27.

PMID:
15688278
[PubMed - indexed for MEDLINE]
Free Article
10.

Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand.

Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, van Griensvan F, Heyward WL, Francis DP, Choopanya K; Bangkok Vaccine Evaluation Group.

AIDS. 2004 Jan 23;18(2):311-6.

PMID:
15075550
[PubMed - indexed for MEDLINE]
11.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.

PMID:
17909315
[PubMed - indexed for MEDLINE]
12.

Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003.

Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; Bangkok Vaccine Evaluation Group.

Int J Drug Policy. 2010 Jul;21(4):296-301. doi: 10.1016/j.drugpo.2009.12.002. Epub 2010 Jan 15.

PMID:
20079620
[PubMed - indexed for MEDLINE]
13.

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.

Eron JJ Jr, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T.

Lancet. 1996 Dec 7;348(9041):1547-51.

PMID:
8950881
[PubMed - indexed for MEDLINE]
14.

Large HIV vaccine trial begins.

Santiago L.

GMHC Treat Issues. 1998 Oct;12(10):1-5.

PMID:
11365900
[PubMed - indexed for MEDLINE]
15.

Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P.

Int J Epidemiol. 1998 Apr;27(2):289-95.

PMID:
9602412
[PubMed - indexed for MEDLINE]
Free Article
16.

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M.

J Infect Dis. 2005 Sep 15;192(6):974-83. Epub 2005 Aug 12.

PMID:
16107949
[PubMed - indexed for MEDLINE]
Free Article
17.

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand.

Vaccine. 2005 Mar 31;23(19):2522-9.

PMID:
15752839
[PubMed - indexed for MEDLINE]
18.

Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand.

Kitayaporn D, Vanichseni S, Mastro TD, Raktham S, Vaniyapongs T, Des Jarlais DC, Wasi C, Young NL, Sujarita S, Heyward WL, Esparza J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):289-95.

PMID:
9803972
[PubMed - indexed for MEDLINE]
19.

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL.

J Infect Dis. 2004 Sep 1;190(5):903-7. Epub 2004 Jul 29.

PMID:
15295694
[PubMed - indexed for MEDLINE]
Free Article
20.

Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S.

JAMA. 2000 Nov 1;284(17):2193-202. Erratum in: JAMA 2001 May 2;285(17):2197.

PMID:
11056590
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk